Genprex's Reqorsa® Gene Therapy Shows Promise for Lung Cancer in Upcoming AACR 2026 Presentation Genprex, Inc. plans to showcase encouraging preclinical findings on Reqorsa®, a gene therapy for lung cancer, at AACR 2026. Key biomarkers related to therapy response will be discussed.

Genprex's Reqorsa® Gene Therapy Shows Promise for Lung Cancer in Upcoming AACR 2026 Presentation #United_States #San_Diego #Lung_Cancer #Genprex #Reqorsa

Genprex Expands Intellectual Property For Cancer Gene Therapy Through Patents In Japan And EU Genprex, Inc. announces patent grants from Japan and the EU for its Reqorsa® gene therapy combined with immunotherapy, enhancing cancer treatment options.

Genprex Expands Intellectual Property For Cancer Gene Therapy Through Patents In Japan And EU #United_States #Austin,_Texas #oncology #Genprex #Reqorsa

Genprex's Patent Approval for Reqorsa® Gene Therapy Enhances Cancer Treatment Potential Genprex, Inc. has secured a patent intent for Reqorsa® gene therapy in combination with PD-L1 antibodies against cancer. This move strengthens their intellectual property.

Genprex's Patent Approval for Reqorsa® Gene Therapy Enhances Cancer Treatment Potential #United_States #Austin #Genprex #Reqorsa #GNPX

Genprex Unveils Promising Results from Acclaim-1 Phase 1 Clinical Trial in Lung Cancer Genprex, Inc. announces significant findings from the Acclaim-1 Phase 1 trial of Reqorsa gene therapy combined with Tagrisso, offering hope for lung cancer patients.

Genprex Unveils Promising Results from Acclaim-1 Phase 1 Clinical Trial in Lung Cancer #United_States #Austin #Genprex #Reqorsa #TAGRISSO

Genprex Expands Clinical Trial Sites for Innovative Lung Cancer Treatment Genprex enhances its lung cancer clinical trials by adding the Gabrail Cancer Center as a site. This move aims to boost patient enrollment for their gene therapy treatments.

Genprex Expands Clinical Trial Sites for Innovative Lung Cancer Treatment #USA #Canton #Genprex #Reqorsa #Acclaim_Trials

Genprex Secures European Patent for Innovative Gene Therapy to Combat Cancer Genprex Inc. has announced the European Patent Office's decision to grant a patent for its Reqorsa® Gene Therapy combined with PD-1 antibodies, enhancing cancer treatment options.

Genprex Secures European Patent for Innovative Gene Therapy to Combat Cancer #USA #Austin #Genprex #Reqorsa #PD-1_Antibodies

Genprex Unveils Promising Data for Reqorsa® Gene Therapy at Major Cancer Conference At the AACR-NCI-EORTC conference, Genprex showcased groundbreaking preclinical results for Reqorsa® Gene Therapy, targeting lung cancer treatment. New findings suggest enhanced patient outcomes.

Genprex Unveils Promising Data for Reqorsa® Gene Therapy at Major Cancer Conference #Genprex #Reqorsa #ALK-EML4

Genprex Sets the Stage with Promising Data for Reqorsa® Gene Therapy at 2025 AACR-NCI-EROTC Conference Genprex's Reqorsa® gene therapy shows promise in treating lung cancer, with exciting preclinical data to be presented at the 2025 conference.

Genprex Sets the Stage with Promising Data for Reqorsa® Gene Therapy at 2025 AACR-NCI-EROTC Conference #USA #Austin #Lung_Cancer #Genprex #Reqorsa

Genprex to Showcase Promising Data on Reqorsa® for Lung Cancer Treatment at AACR-NCI-EROTC Conference Genprex will present promising preclinical findings on Reqorsa® Gene Therapy for lung cancer at the upcoming conference, illustrating its potential as a transformative treatment.

Genprex to Showcase Promising Data on Reqorsa® for Lung Cancer Treatment at AACR-NCI-EROTC Conference #United_States #Boston #Lung_Cancer #Genprex #Reqorsa

Genprex Expands Patent Portfolio for Gene Therapy on Cancer Innovations Genprex, Inc. strengthens its cancer treatment capabilities by securing multiple patents for Reqorsa® Gene Therapy, enhancing immune checkpoint blockers.

Genprex Expands Patent Portfolio for Gene Therapy on Cancer Innovations #USA #Austin #Genprex #Reqorsa #PD-L1

Genprex to Showcase Acclaim-3 Trial Design Evaluating Reqorsa® for Lung Cancer at ASCO 2025 Genprex will present the Acclaim-3 clinical trial design for its Reqorsa® gene therapy targeting extensive stage small cell lung cancer at the ASCO Annual Meeting in 2025.

Genprex to Showcase Acclaim-3 Trial Design Evaluating Reqorsa® for Lung Cancer at ASCO 2025 #United_States #Chicago #Genprex #Reqorsa #ASCO2025

Genprex Expands Its Gene Therapy Portfolio with Exclusive Licensing Agreement for Glioblastoma Treatment Genprex has secured an exclusive license agreement with UTHealth Houston for advanced gene therapy technology aimed at treating glioblastoma. This moves the company's treatment options forward significantly.

Genprex Expands Its Gene Therapy Portfolio with Exclusive Licensing Agreement for Glioblastoma Treatment #United_States #Austin #Genprex #Reqorsa #UTHealth

Genprex Unveils Promising Results for Reqorsa Gene Therapy at AACR 2025 Genprex shares encouraging preclinical results for Reqorsa gene therapy in tackling Ras inhibitor-resistant lung cancer at the AACR 2025 event.

Genprex Unveils Promising Results for Reqorsa Gene Therapy at AACR 2025 #USA #Chicago #Genprex #Reqorsa #AACR_2025

Genprex Partners with NYU Langone Health for Mesothelioma Treatment Breakthrough Genprex has formed an exclusive agreement with NYU Langone Health for its Reqorsa gene therapy, targeting difficult-to-treat mesothelioma. This partnership aims to advance clinical studies and enhance treatment options.

Genprex Partners with NYU Langone Health for Mesothelioma Treatment Breakthrough #United_States #Austin #NYU_Langone #Genprex #Reqorsa

Genprex Announces Presentation of Acclaim-3 Clinical Trial Design at ASCO 2025 Genprex, Inc. will present its trial design for Acclaim-3, examining Reqorsa Gene Therapy for lung cancer, at the 2025 ASCO Annual Meeting.

Genprex Announces Presentation of Acclaim-3 Clinical Trial Design at ASCO 2025 #USA #Chicago #Genprex #Reqorsa #Acclaim-3

Genprex to Showcase Promising Data on Reqorsa® Gene Therapy for Lung Cancer at AACR Annual Meeting 2025 At the upcoming 2025 AACR Annual Meeting, Genprex will present encouraging preclinical findings on Reqorsa®, a gene therapy aimed at treating lung cancer, showcasing innovative cancer treatment potential.

Genprex to Showcase Promising Data on Reqorsa® Gene Therapy for Lung Cancer at AACR Annual Meeting 2025 #United_States #Chicago #Lung_Cancer #Genprex #Reqorsa

Genprex Begins Acclaim-3 Phase 2 Trial for Gene Therapy in Lung Cancer Patients Genprex has initiated the Phase 2 expansion for the Acclaim-3 study, focusing on Reqorsa gene therapy combined with Tecentriq to treat extensive stage small cell lung cancer.

Genprex Begins Acclaim-3 Phase 2 Trial for Gene Therapy in Lung Cancer Patients #United_States #Austin #Genprex #Reqorsa #Tecentriq

Genprex Advances to Phase 2 in Acclaim-3 Clinical Trial Evaluating Gene Therapy for Lung Cancer Genprex, Inc. has gained approval to proceed to Phase 2 of the Acclaim-3 clinical trial for Reqorsa® gene therapy combined with Tecentriq® for extensive-stage small cell lung cancer.

Genprex Advances to Phase 2 in Acclaim-3 Clinical Trial Evaluating Gene Therapy for Lung Cancer #USA #Austin #Genprex #Reqorsa #Tecentriq